Compare Nucor Corporation (NUE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Nucor (NUE) trades at $246.14, down 1.96% on the day, amid a neutral technical signal with mixed moving averages and oscillators. Recent earnings show Q1 and Q2 2026 beats, but Q3 guidance of $5.75 EPS is pending. Revenue for 2025 was $32.49B with a net income margin of 7.99%, while 2026 projections indicate a rebound to $36.1B revenue and 7.98% margin. The company maintains a strong balance sheet with $4.14B cash and a debt-to-asset ratio of 20.23% for 2025.

Outlook remains cautiously optimistic with a consensus price target of $266.88, implying ~8% upside, supported by 57.58% analyst buy ratings. Risks include competitive pressures from a new $15B Iowa steel mill and volatile steel prices, but Nucor's low-cost operations and dividend consistency (214th consecutive payout) provide stability. Investors should monitor Q3 earnings for confirmation of growth trajectory amid sector headwinds.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.